Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric
antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive
metastatic ovarian and endometrial cancer.